Company intelligence / Profile preview

Mirna Therapeutics

Austin, Texas, United Statesinvestor.synlogictx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Mirna Therapeutics was a clinical-stage biopharmaceutical company focused on developing microRNA-based oncology therapeutics. Its lead candidate, MRX34—a mimic of miR34a encapsulated in a liposomal nanoparticle—entered Phase 1 trials but the study was halted due to immune-related serious adverse events. The IND for MRX34 remains on full clinical hold. In August 2017, Mirna merged with Synlogic and ceased independent operations.

Therapeutic areas: Oncology
Modalities: RNA therapySynthetic oligonucleotideLipid nanoparticle delivery therapy
Industry: Biotech

Drug pipeline

1 asset

MRX34

Phase 1

Indications: Cancer

Beyond the preview

Go deeper on Mirna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirna Therapeutics.

Explore the full profile